A Comparative Study of Intravenous Nalbuphine and Hydromorphone Combinations for Post-Cesarean Pain Relief

For many women, a cesarean section (CS) brings the joy of a new baby—but also intense post-operative pain. This pain isn’t just uncomfortable: it can delay breastfeeding, slow physical recovery, and even increase risks of complications like postpartum depression. Finding the right pain relief that targets both the incision (somatic pain) and uterine cramping (visceral pain, worsened by oxytocin used to prevent bleeding) is critical. A 2020 study from Zhejiang University’s Women’s Hospital offers clarity on one promising solution: combining hydromorphone (a potent opioid for somatic pain) with nalbuphine (a mixed opioid agonist-antagonist for visceral pain) via patient-controlled intravenous analgesia (PCA).

Study Overview: Finding the Ideal Nalbuphine Dose

Led by Chun-Yun Huang, Shu-Xi Li, Mei-Juan Yang, Li-Li Xu, and Xin-Zhong Chen from the Department of Anesthesia at Women’s Hospital, Zhejiang University School of Medicine, the study aimed to answer a key question: What concentration of nalbuphine, paired with a fixed dose of hydromorphone, provides the best pain control with the fewest side effects for post-CS patients?

The team enrolled 114 healthy women (aged 25–35, ASA physical status II) undergoing elective CS. All received epidural anesthesia during surgery and were randomized into three groups, each using a PCA pump to deliver hydromorphone (0.05 mg/mL) plus different nalbuphine concentrations:

Group LN: Low nalbuphine (0.5 mg/mL)
Group MN: Medium nalbuphine (0.7 mg/mL)
Group HN: High nalbuphine (0.9 mg/mL)

The PCA pump was set for safety: a steady 2 mL/h infusion, 2 mL boluses (self-administered doses) every 10 minutes, and a 14 mL hourly limit. Researchers tracked:

Pain intensity: Visual Analog Scale (VAS) scores for incisional pain (rest/movement) and uterine cramping (rest, breastfeeding, oxytocin infusions).
PCA use: Number of bolus requests, total medication used, and how often requests were granted (delivery/demand ratio).
Satisfaction: Patient ratings of pain management (1 = very unsatisfied to 5 = very satisfied).
Side effects: Sedation (Ramsay Sedation Scale), urinary retention, time to first flatus (gas), vomiting, and newborn Apgar scores (to check breastfeeding safety).

Key Results: The “Goldilocks” Dose for Pain and Safety

The study’s findings highlight a balanced approach—the medium nalbuphine concentration (0.7 mg/mL) offered the best mix of pain relief and minimal side effects:

1. Better Pain Control for Uterine Cramping

Uterine pain: Women in the medium (MN) and high (HN) groups reported significantly less cramping pain at rest, after breastfeeding (which triggers oxytocin release), and during oxytocin infusions compared to the low (LN) group. For example, 4 hours post-surgery, uterine cramping pain scores were 2.0 (MN) and 1.9 (HN) vs. 3.0 (LN).
Incisional pain: All groups had similar, well-controlled pain (VAS scores 1–4), thanks to the fixed hydromorphone dose.

2. Fewer PCA Requests = More Effective Pain Relief

Women in the low group pressed their PCA pump 21 times on average (vs. 15 in MN, 13 in HN) and used more medication overall—signs their pain wasn’t well-managed.
The medium and high groups had a higher delivery/demand ratio (81%–83% vs. 75% in LN), meaning more of their pain requests were met (a marker of effective analgesia).

3. Higher Satisfaction, Fewer Side Effects

Satisfaction: Women in the medium group rated their pain control significantly higher (4.6 out of 5) than those in the low (3.9) or high (4.4) groups.
Sedation: The high group had more sedation (higher Ramsay scores) at 8–12 hours post-surgery—meaning moms were sleepier and less able to care for their babies.
Recovery: The medium group had faster time to first flatus (40 hours vs. 43 in LN, 48 in HN) and less urinary retention (5.3% vs. 11.1% in HN)—critical for regaining normal function.
Breastfeeding safety: Both drugs transfer very little to breast milk (nalbuphine: ~0.59% of maternal dose; hydromorphone: ~0.67%). All newborns had perfect 5-minute Apgar scores (10/10), so breastfeeding was safe.

What This Means for Post-CS Patients

The study’s biggest takeaway? A combination of hydromorphone 0.05 mg/mL + nalbuphine 0.7 mg/mL via PCA is the sweet spot for post-CS analgesia. It:

Controls both incisional and uterine pain effectively.
Minimizes side effects like sedation and urinary retention.
Improves patient satisfaction and recovery (faster first flatus, less need for extra pain medication).

For new moms, this means less pain, more energy to bond with their baby, and a smoother transition to breastfeeding—without worrying about excessive sedation or unsafe drug exposure for their infant.

Limitations and Future Research

While the study provides strong evidence, it has minor gaps:

Researchers didn’t track how pain control affected lactation initiation or prolactin levels (hormones that drive milk production).
A larger sample size could confirm long-term safety (e.g., rare side effects like pruritus or dizziness).

Conclusion: A Clear Recommendation for Anesthesiologists and Patients

This randomized, double-blind study (registered at the Chinese Clinical Trial Registry, ChiCTR1800015014) offers a evidence-based solution for post-CS pain. The medium nalbuphine concentration balances effective pain relief with safety—critical for new moms prioritizing both their recovery and their baby’s well-being.

Cite the Original Study

Huang CY, Li SX, Yang MJ, Xu LL, Chen XZ. A comparative study of three concentrations of intravenous nalbuphine combined with hydromorphone for post-cesarean delivery analgesia. Chinese Medical Journal. 2020;133(5):523–529.
Funding: National Natural Science Foundation of China (No. 81471126).
DOI: doi.org/10.1097/CM9.0000000000000678

Was this helpful?

0 / 0